Price on 05/09/97: Rs 26
This stock lost over 19 per cent of its market capitalisation over the previous week. This steep fall is due to its plans of selling its Ahmedabad-based formulation unit. The company is also selling five branded products to repay its debt obligation towards financial institutions. The product categories of the brands which the company is planning to sell are analgesic, amoebic, cardiovascular, antihistamine and antibiotic. It has defaulted on both the interest and the principle repayment to financial institutions. FIs have an exposure of Rs 360 crore in Core Healthcare. The companys turnover for the 15-month period ending June 1996 was Rs 244 crore and the unit which is to be sold off contributed about 11 per cent to the turnover.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app